Due to the special nature of medicines, returns and exchanges are not supported.
Final delivery from the nearest overseas warehous NEW


Acalabrutinib is a targeted therapy that inhibits the function of Bruton’s tyrosine kinase (BTK). BTK is a
Intracellular proteins may be overexpressed in malignant B cells. Acalabrutinib is a BTK inhibitor
agent that blocks BCR signaling and inhibits the growth and survival of malignant B-cell tumors.


Featured products

Laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor.